|Bid||41.6900 x 500|
|Day's Range||45.6900 - 48.6600|
|52 Week Range||37.3500 - 55.3800|
|PE Ratio (TTM)||-20.04|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
The T-Force GREEN study was a Phase 2 study designed to evaluate the safety, tolerability, and efficacy of INGREZZA™ in children and adolescents with Tourette syndrome (TS) (NCT02679079). It was a randomized, double blind, placebo controlled, multi-dose, parallel group trial of approximately 90 children and adolescents. Patients received once-daily dosing of INGREZZA™ or placebo in a 1:1:1 fashion during a six-week treatment period.
Neurocrine may have left the door open for Teva to get an early lead in Tourette's syndrome, an analyst said Wednesday.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug . The company announced ...